Biomerica Inc (BMRA) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider...

Form 8-K - Current report

Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain

Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from...

Biomerica Reports First Quarter Fiscal 2025 Financial Results

Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer

- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi...

Biomerica Reports Fiscal 2024 Year End Results

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers

inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology...

Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and...